Company intelligence / Profile preview

TurnSole Biologics

Pécs, Hungary

Ownership: Private
Development stage: Other

Overview

TurnSole Biologics is a specialty pharmaceutical company based in Hungary that focuses on developing personalized medicines for major clinical unmet needs. The company's lead program, TS-020, is a repurposed formulation of azacitidine being evaluated in a Phase Ib/II clinical trial for the treatment of hospitalized patients with acute COVID-19. TurnSole's technology aims to interfere with viral replication and modulate the immune response to prevent disease progression in severe infections. The company is headquartered in Pécs and maintains operations in Budapest, positioning itself as a developer of rapid-response personalized therapies.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

South-Pest Central Hospital (DPCK)

Beyond the preview

Go deeper on TurnSole Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TurnSole Biologics.

Explore the full profile